Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical Industries Ltd Announces U.S. FDA Approval of Three Times a Week COPAXONE


Tuesday, 28 Jan 2014 06:30pm EST 

Teva Pharmaceutical Industries Ltd:Says the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for three times a week COPAXONE a new dose of COPAXONE.Says this new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis.Says the FDA approval is based on data from the Phase III Glatiramer Acetate Low-Frequency Administration (GALA) study of more than 1400 patients.